Complete evaluation of the toxicity of a new chemical entity requires critical analysis of the pattern of positive and negative findings in all types of toxicity tests, pharmacokinetics and metabolism in the species examined, and correlation of the effects with information about its pharmacodynamic and pharmacological properties. The goal is to obtain sufficient understanding of the mechanisms underlying the therapeutic and toxic effects of the compound to permit a well-supported extrapolation from the test to the target species. The Expert Report system in the European Community is based on comprehensive 25-page reviews of information about a compound arranged under 3 headings: Chemistry and Pharmacy, Pharmacology and Toxicology, and Clinical Studies. Each section requires a searching review of the experimental work and the relevant literature, integration of the findings, and then careful correlation among these 3 main areas of knowledge to indicate the circumstances of safe and effective use of the drug.
INTRODUCTION
The basic elements in evaluation of a candidate medicine are its quality, safety, and efficacy. Each component of that trinity represents an extended complex of information and evaluations, which must be carefully integrated to produce a comprehensive assessment of the properties, actions, and weaknesses of the new compound. This is now done formally in the European Community (EC) by the requirement for the applicant for a "Marketing Authorisation" (NDA) for a new chemical or biological entity to provide Expert Reports (ERs) on the Chemistry and Pharmacy ("quality"); pharmacodynamics, pharmacokinetics, and toxicity ("safety"); and actions and adverse effects in the target species ("efficacy"). Each separate report provides a critical analysis and conclusions about the topics covered and their implications as well as an evaluation of relevant parts of the other ERs ( Fig. 1 ).
Together, therefore, they provide a fully integrated; concise review of the composition, toxic actions, and therapeutic and clinical effects of the substance, in which all sources ofdata are ultimately combined to produce definitive recommendations for clinical use, precautions, and warnings about th2 NCE.
The ER system may be operated in different ways by regulatory bodies in North America, the Far East, and elsewhere, but the information, assessment, and correlation of different sources of data are so alike that there is much interesteverywhere in obtaining and using EC-style ERs.
ERs provide the manufacturer with a critical analysis of the adequacy and weaknesses of a drug development programme and with the opportunity to advance the best arguments for the NCE; they offer a regulatory agency a ready-made guide to the nature and properties of an NCE, and they can be used to compile the Summary Basis of Approval or the Summary of Product Characteristics. Thus, they can represent both an opportunity to present a compound and its benefits and problems, and, because of the analysis and integration of data, they also represent a broad assessment of the quality of all the work done.
ORIGW AND NATURE OF THE
ER SYSTEM IN THE Ec The need for ERs and their nature has been defined in various EC directives on Multistate Applications (3) and on Biotechnology/High Technology (Concertation) applications (4), which are derived from the basic directives on marketing applications (i.e., NDAs) for medicines (1, 2). Their nature and scope are more helpfully described in a recent monograph (5) . .
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Within 25 pages, plus associated tables of summary data, each ER must review all the available information about the relevant aspects of the NCE, note any missing data according to current convention, and then in an analytical and critical fashion discuss the full results ofthe completed studies, their adequacy, and any weaknesses; their physiological, pharmacological, and toxicological significance in the Preclinical ER (and the corresponding chemical and pharmaceutical and clinical data in the other ERs); their implications for the planned clinical uses ofthe compound; and their general nature as a guide to regulating therapy with the NCE, predicted adverse effects, special implications and problems, and anything else that an intelligent and knowledgeable observer might reasonably wish to know about the NCE and its actions.
The ER is accompanied by a set of detailed tables that summarise all the factual information in a predefined and concentrated fashion, so the report itself will form an essay on knowledge of the NCE and its good and bad points.
The 3 ERs together answer all the questions in the 3 areas that cover every product license application for an NCE: quality, safety, and efficacy. They do so by giving the author ofeach report a structured but free opportunity to assess the total scope of the evidence for and against the NCE within the limits of the field being considered, and then requiring those arguments to be integrated in relation to information in the other ERs, and finally to conclude why the NCE should be approved for use in humans or animals for given indications, with what likely adverse effects, and hence with what restrictions and precautions.
The set of 3 ERs is accompanied by the Summary of Product Characteristics, or SPC, which is a concise precis of all the clinically relevant data, largely based on the ERs, and on which the all important data sheet and labelling recommendations are based.
In essence, the ERs should summarise the case for and against the NCE. They require each expert to stand back and dispassionately examine the development work done in hidher and other areas for its strengths and weaknesses and, thus, to convince other scientists and clinicians that both the benefits and risks of the compound have been comprehensively considered and that its good points outweigh any risks it might carry.
The ERs, plus full supporting information, etc., must be provided in standard format to the Rapporteur-the national agency that deals with the licensure of pharmaceuticals in the selected member state ofthe EC. That agency will prepare a "reasoned assessment" of the case for and against the drug, the ERs to the Committee on Proprietary Medicinal Products (CPMP) of the EC as the basis for recommending approval of the application (NDA). In subsequent correspondence via the Rapporteur, and possibly a hearing before the CPMP, any concerns and questions about the NCE and its effects raised by the other 1 I member states of the EC must be answered, and then the basic decision about licensing of the NCE and permitted indications will be given. This is the centralised decision-making process, as for a new biotechnology product, and for a simultaneous application to several EC countries ("multistate"), but the need for ERs now generally applies to all applications for new drugs, even those made only in 1 EC country.
SCOPE OF THE 3 ERS
The Clieiuistry aiid Pliarniacy ER presents information confirming the structure of the NCE,'or confirming its identity if it is a biological or biotechnology product, the route of synthesis and purification, the pharmaceutics involved in its formulation, and the analytical procedures and controls employed at each stage in the manufacturing process as well as an account of the necessary stability testing and related studies.
The Preclinical ER provides all the evidence about the mode of action of the NCE, i.e., its pharmacodynamics and primary and secondary (safety) pharmacology, its kinetics and metabolism in animals, and all the conventional and any special or investigative toxicity tests. It will consider the adequacy of these studies in-terms of the pathogenetic mechanism and consequences of the target disease and the comparability or divergence of the kinetics and metabolism and the pharmacology in all the iii rdvo and iiz virro test systems. It will also consider their implications for predicting and understanding therapeutic and adverse effects in the target species, vulnerable groups, and any special problems important in a risk-benefit assessment (e.g., drug interactions, reproductive hazards, impurity profile).
Having defined the diseases studied, the Cliiiical EK must describe completed Phase 1-111 studies in .terms of subjects investigated, pharmacodynamics, kinetics and dietabolism, therapeutic efficacy, and the dose-response relationship. The causes and mechanisms of desired and unwanted actions must be explained, and so must the confidence (statistical power) of the trials.
The patient groups, dosage regimen, and precautions in the treatment monitoring programme must be described as well as any special precautions, limitations on use, and any other conclusions relevant largely based on the ERs, which isforwarded with to safe use of the substance. From this it will be seen that there is a considerable overlap between the 3 ERs-one of the levels of integration required ( Fig. 1) . Thus, the Preclinical ER must refer to the Chemistry and Pharmacy ER, for example, in considering the relevance of the purity and stability of the compound and formulation used in the pharmacological and toxicity studies, including stereoisomerism, the nature and actions of excipients employed, and the actions of any impurities.
It must look forward to the Clinical ER, first, by stating the desired therapeutic or prophylactic actions and their mechanisms, and comparative kinetics and metabolism, thus presenting the validity and any weaknesses of the pharmacological and toxicological test systems. Then it must provide conclusions about the activities and toxicity of the substance, and of its formulations, in such a way as to indicate what might occur in clinical practice and why. In this way, it will provide much of the basis for the essential "risk" part of the ultimate riskbenefit analysis on which successful licensing depends.
The Clinical ER, in turn, will assess the adequacy of the preclinical evaluation in its relation to human (or other target species) pharmacodynamics, pharmacokinetics, and toxicity. It will be related to the Chemistry and Pharmacy ER in terms of the importance (or irrelevance) of impurities, stability, and any special pharmaceutical aspects of the 'formulations and method of therapeutic application.
The ideal position is that the regulatory decision could be based solely on reading the 3 ERs and their supporting summary tables. This may not always be realised in practice, but a set of good ERs will go a very long way toward achieving this goal.
STRUCTURE OF THE PRECLINICAL ER
The Preclinical ER is considered in detail because it is the ER most relevant to safety and it is the theme of the symposium, but the account is broadly applicable to the other ERs, too.
An ER must follow the pattern described in the guidelines of the CPMP of the EC (see Tables I and  11 ). It compiises sections in sequence that deal with the following themes, always progressing from lower to higher species, and from in vifro to in vivo. Each related group of experiments in a subject area should be grouped together. The nature and results of each group of related studies should be discussed and then the conclusions analysed for strength, mechanism or cause and its likely implications, and the reasons for the absence of anticipated findings considered. Finally, the entire pattern of pharmacology and pharmacodynamics, kinetics, and toxicity is reviewed, emphasising the use of all the information to understand the aetiology and pathogenesis effects seen, their relationship to the treatment employed, and their consequences in predicting risk to patients-the essential validity of the experiments.
The main topics covered (and the absence of an entry under any heading should be justified) are as follows.
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Pliarinacodyrramic Activity Related to Therapeutic Eflects
The topic of pharmacodynamic activity should comprise (in vivo and then in vitro) all the pharmacology and basic biochemical studies of effects; for example, for an antibiotic, what species of organism are affected and how; was resistance found and what was its mechanism; was resistance transferable via plasmids or other means; any cross-resistance to other antibiotics? What doses and plasma levels were required for activity? How effective was it in standard laboratory models of relevant infections, both on its own and in comparison to known agents? Any special exploration of efficacy suggested by its structure and actions (e.g., resistance of a penicillin analogue to P-lactamases)? For a vasodilator hypotensive, the information might well include the dose-response relationship of the effect or blood pressure, cardioactivity and regional haemodynamics, the mechanism of action on, say, vascular smooth muscle and on endothelial cells, and their responses to nitric oxide, prostaglandins, tachykinins, and autocoids.
This section will come from the work of pharmacologists, biochemists, and other specialists (e.g., enzymologists, immunologists, membrane and receptor experts) as may be appropriate.
Other Pliarinacodynainic Actions
General functional actions on the major body systems, namely the nervous, cardiovascular, respiratory, renal, and gastrointestinal systems, should also be addressed. Sometimes endocrine and other metabolic and blood clotting actions are included here. Of necessity, the studies will be done in intact animals first, and any special activities may be explored in in vitro procedures.
The 2 preceding sections and the subsequent account of toxicity may all include information about interactions and other possible adverse effects as well as suggestions for their avoidance and treatment, including antidotes.
Plrarriiacokiiretics and Metabolism
By species, and if done, by in vitro system, how is the substance handled by the species used, at least in the toxicity tests; what is its disposition and elimination, and by what routes; and how is it metabolised? What are the consequences of these observations for the validity of the toxicity tests (e.g., species-specific factors, active metabolites, nonlinear kinetics) and for common processes in target species, such as the effects of disease and physiological variation on disposition and metabolism, enzyme induction, unusual concentration or binding at a site in the body, possible drug interaction via actions on enzymes or protein binding, etc.?
Following the effecjs of metabolism on stereospecificity has become of increasing importance, as has detailed exploration of interactions with identified hepatic enzymes, because of their species-specific role in local and systemic toxicity.
A major aim is to validate all the toxicity tests, especially those done in viro, by demonstrating the relationship between dose exposure (internal) and effect, thus helping to indicate the confidence with which the effects can be extrapolated to the target species.
It is very important to compare the principal findings in animals and humans (or other target species), as an essential part of the discussion of the validity of the preclinical studies, and the ways in which they may support or diverge from human experience.
Toxicity
Toxicity is dealt with under the headings acute, subacute, and chronic, always starting with the lowest species and ending with the highest (e.g., moving from the mouse to rat to dog to nonhuman primate). In each case, it is best to summarise concisely what was done (e.g., species, numbers, doses; "standard" experiment or indicate the ways in which nonconventional), what was found (nature, incidence, severity, and reversibility),.and what was expected but not found. Note blood levels of the NCE and metabolites or other information about exposure. Compare the results of the diverse experiments to indicate the nature, pattern, progression, and consequences of the actions and their relationship to dose and duration of treatment.
Then-and this is the crucial and both the most difficult-and interesting part-discuss the likely causes of the effects found, bringing together all the functional, pharmacokinetic, and other toxicity data, including comparisons with other substances and biological processes reported in the literature, or as investigated during development of the agent in question. Examples might include relating profound hypotension (at a given dose) to lesions in the myocardium, certain blood vessels, and the brain; linking, say, enlargement of the liver with hyperplasia of the thyroid and anterior pituitary; associating a platelet activating factor antagonist with changes in leucocyte and smooth muscle function; or associating a cytokine with selective proliferation or depression of lymphoid cell populations and appropriate changes in, say, the blood count and in the size and detailed histological appearances of relevant organs as well as in the state and normalcy of specific immune functions. This is a major test of DAYAN TOXICOLOGIC PATHOLOGY the expert's analytical and integrative skills, and it is even more searching as a test of the adequacy of the programme of preclinical investigations.
Gciietic Toxicity
What procedures were done iii vitro and iii vivo and what was found? What are the clinical implications?
Carciiiogeiiicity Testing
What was the nature of the experiments and the findings? Their relationship to the results of genotoxicity and toxicity testing should be considered, as well as to kinetics, in assessing the internal validity of accepting or denying an apparent excess of neoplasms ("weight of evidence" approach), and their external applicability to the target species. Reasons should be.given for omitting l or more tests (e.g., if the NCE were intended only for brief treatment, or as physiological replacement therapy).
R cp rodiict io it Testing
As usual, within the broad categories of Segment I, 11, and 111 procedures, what studies were done, what was found, and how might it have been influenced .by pharmacodynamics and kinetics? Proposed mechanisms should be supported by facts as far as possible and by strict analogies with known agents.
Special Tests
A special tests section should cover any nonconventional investigations done because of any other activities suggested by structure or actions of the substance. For example, if a hydrazino-derivative were being developed as a cytotoxic agent, what effect might it have on monoamine oxidase? Would a novel endorphin derivative affect lymphocyte function via cell surface receptors? Could an NCE that stabilised bone structure have an effect on normal remodelling and turnover, or on ectopic or dystrophic calcification? The aim is to be broad but relevant, while still discussing what work was done, or why studies were not done, and the importance of their absence in evaluating the compound.
General Discirssioii
While not being repetitious, a general discussion (Table 111) should briefly summarise the detail of the preceding sections and then most of it should be devoted to presenting a general synopsis of the substance and its actions, carefully related to the findings in the other ERs. The key theme throughout is to describe the actions and toxic effects and to relate them to pharmacological, biochemical, and physiological responses and regulatory counter-re-sponses, to the dose or, better, the active metabolite level, and to the therapeutic and pathogenetic mechanisms of the activitiesJound. This requires a high level of integration of knowledge and understanding of the fundamental biochemical, immunological, and physiological modes of action at various dose levels with the therapeutic and unwanted (toxic) actions, whether detected as functional, dynamical, chemical, haematological, or pathological changes [e.g., linking depletion of hypothalamic catecholamines by a re-uptake inhibitor (e.g., reserpine), with sedation, hypotension, and changes in pupillary responses, sexual arousal, etc., and with increased prolactin secretion, mammary hyperplasia and tumours, altered growth rate, changes in liver foci, reduced heart weight, impaired fertility, etc.-all at relevant dose levels]. Based on knowledge of the relative internal exposure (dose level and kinetics) in different species, plus understanding of differences in physiological control mechanisms and their sensitivity, the correlated analysis in the Preclinical ER can be taken up in the Clinical ER to provide a framework for understanding the activity-dose-toxicity relationship and, hence, the goals and limitations on clinical use.
The discussion should include the expert's own assessment of the overall biological activities of the NCEas formulated and the implications for its therapeutic use, contraindications, specific precautions and interactions, and suggestions for monitoring of specific side effects.
General Coitcltisioits
The last, brief section on general conclusions (Table IV) should draw all the evaluations together in a concise statement of the therapeutic and toxic activities of the compound at different dose levels, ready to guide the clinical assessment. The detail of each experiment, animal or iiz vitro system, numbers, treatment regime, investigations and findings, and Good Laboratory Practices status should be summarised in a series of standardised tables. Results from the published literature can be cited, and, as far as possible, it may be helpful to summarise them in tabular form, too.
WHO CAN BE AN EXPERT?
How MANY Do You NEED?
The CPMP guidelines are deliberately and helpfully vague by referring just to someone who has appropriate qualifications and experience, as will be shown in the CV that must be provided for each expert.
Different sections within the Preclinical ER may be written by different people, who may or may not have been responsible for individual experiments. They may be whole-time employees ofthe applicant (manufacturer) or they may be extramural consultants employed just to provide all or part of the ER. It is feasible for in-house and external persons together to write an ER. In practice, it is likely that help will be required ifit is necessary to span subjects as diverse as molecular biology, statistical analysis, and histopathology. Ultimately, however, 1 person has to take responsibility and sign the complete report, which means accepting its contents and arguments as a fair and comprehensive account of the properties of the NCE and their relationship and implications for the other ERs and, thus, for the therapeutic acceptability of the substance. Close coordination among the authors of the 3 ERs is essential, and they must have the opportunity to consider each others' interpretations and comments. These requirements may affect the seIection of the expert, because they will raise questions about ease of access, working language, and ready availability to deal with questions raised by the rapporteur country and by the CPMP itself.
How TO WRITE AN EXPERT REPORT The expert is in a curious position, because very late in development of a drug hidher role is to evaluate and criticise the entire process, possibly revealing a major weakness in years of work! This has at 1.
2.
least four consequences:
The expert, whether in-house or an external consultant, must have the assurance of complete independence and full managerial support, even if drafting the report appears to result in criticism of completed work. Total access to all in-house information is mandatory for the expert as well as to relevant pub-Iished literature. It is vital, too, that each expert sees the other ERs in draft, so that their inter- 
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relationships can be discussed and integration achieved. Equally important, the final signatory of each ER must have free access to the scientists responsible for each area of investigation and testing, so that a full explanation can be given for each area of the preclinical work by those responsible for its design and conduct. The draft ER must be reviewed by all the preclinical scientists. It is also very helpful if it can be reviewed for clerical accuracy, especially the detailed summary tables, generally by someone from the regulatory affairs department.
TIMING, TIME, AND SUPPORT
It is a truism that the ideal way to write an ER would be to begin on the first day that a development programme is begun, so that the need for critical analysis and review and integration is taken into account at all stages. Failing that sometimes impractical procedure, it is still worth identifying the expert early on and continually seeking hidher views on the development programme. In this way, concerns raised by the synoptic integration can be accommodated as they arise, rather than leading to awkward delays and acrimony just before the marketing application.
The expert will require reasonable clerical and administrative support and a guarantee of sufficient time to do the job. Each case is different but even writing the Preclinical ER and its tables for a narrow range biotechnology product, say, or a cytotoxic agent may well take 3-4 wk of working time (say 2 calendar mo), and a major NCE may well require up to 4 calendar mo to complete, depending on how much support is available to compile tables and collate reports and how easy it is to arrange discussions between, say pharmacokineticists and reproductive toxicologists, or with chemical analysts and pharmaceutical engineers, or with clinicians and regulatory affairs managers, to answer concerns and produce an ordered and comprehensive ER.
STRENGTHS AND WEA.KNESSES OF THE
ER SYSTEM The value of the ER in general is that it brings into a unitary frame all the chemical and pharma-
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TOXICOLOGIC PATHOLOGY ceutical data, information about desired and hazardous biological activities and kinetics and the clinical evidence about therapeutic benefit and adverse effects. In this way, and in each separate ER dealing with quality, safety, and efficacy, all the positive and negative evidence is presented and tested for appropriateness, adequacy, and strength and for comprehensiveness. Information about actions, doses, exposure, and proven or likely causes can be integrated to show the real value and risks of the NCE. The principal and inevitable weakness is that, like any other process of individual or group enquiry, it depends on the scope and strength of the writer's inquisitorial faculty and imagination, tempered by the concrete focus of the given compound, its actions, and the momentum of a drug development programme.
The ER system will force the drug developer to be both general and explicit in presenting the NCE, and if that is well done, and a good (but not complaisant or superficial) case presented for the drug, it is likely to enjoy relatively smooth and quick regulatory progress (excepting any biases of individual regulators). Correspondingly, a poor or overly optimistic analysis will rebound against the expert assessment, and, in addition to the time required for the regulatory agency to compile its own ERs as the basis for its own assessment, it must engender suspicion and the delay of detailed enquiries.
In essence, the ER should present the best sci-entific case for and against an NCE and, ifwell done, should encourage clear thinking and equitable assessment, leading to a sfrong justification for turning the novel drug into a new medicine.
